Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Stem Cell Research

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 46 articles: HTML format

Single Articles

January 2023
1. LIN M, Wu X, Zhang L, Li L, et al
   Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
   Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
   PubMed     Abstract available
   
   
   
2. GAUT D, Oliai C, Mead M
   Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
   Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
   PubMed    
   
   
   
3. KALOYANNIDIS P, Al Zayer M, Al Darweesh M, Al Batran M, et al
   Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
   Leuk Lymphoma. 2023 Jan 11:1-4. doi: 10.1080/10428194.2022.2164195.
   PubMed    
   
   
   November 2022
4. MOYER AM, Hashmi SK, Kroning CM, Patnaik M, et al
   Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
   Leuk Lymphoma. 2022 Nov 30:1-8. doi: 10.1080/10428194.2022.2151838.
   PubMed     Abstract available
   
   
   
5. KUMAR L, Sahoo RK, Kumar S, Baa AK, et al
   Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
   Leuk Lymphoma. 2022 Nov 23:1-10. doi: 10.1080/10428194.2022.2148214.
   PubMed     Abstract available
   
   
   
6. PIANKO MJ
   Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation.
   Leuk Lymphoma. 2022 Nov 18:1-2. doi: 10.1080/10428194.2022.2148219.
   PubMed    
   
   
   
7. MCCLELLAND J, Wong E, Grigg A
   Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.
   Leuk Lymphoma. 2022 Nov 11:1-5. doi: 10.1080/10428194.2022.2142054.
   PubMed     Abstract available
   
   
   
8. KREFT A, Schulze L, Ries I, Schindeldecker M, et al
   Histological diagnosis of acute graft-versus-host disease in different sites of the upper gastrointestinal tract with correlation to endoscopic findings.
   Leuk Lymphoma. 2022 Nov 6:1-7. doi: 10.1080/10428194.2022.2142056.
   PubMed     Abstract available
   
   
   
9. MIKULSKI D, Koscielny K, Nowicki M, Wawrzyniak E, et al
   Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
   Leuk Lymphoma. 2022 Nov 1:1-9. doi: 10.1080/10428194.2022.2136946.
   PubMed     Abstract available
   
   
   October 2022
10. STEWART T, Dowling M, Janson B, Siderov J, et al
    Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
    Leuk Lymphoma. 2022 Oct 25:1-3. doi: 10.1080/10428194.2022.2136945.
    PubMed    
    
    
    
11. GARDENSWARTZ A, Mehta B, El-Mallawany NK, van de Ven C, et al
    Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, a
    Leuk Lymphoma. 2022 Oct 19:1-4. doi: 10.1080/10428194.2022.2133542.
    PubMed    
    
    
    
12. D'ANGELO C, Sudakaran S, Asimakopoulos F, Hematti P, et al
    Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Oct 11:1-11. doi: 10.1080/10428194.2022.2131410.
    PubMed     Abstract available
    
    
    September 2022
13. VILLALBA A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, et al
    Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
    Leuk Lymphoma. 2022 Sep 20:1-10. doi: 10.1080/10428194.2022.2123229.
    PubMed     Abstract available
    
    
    
14. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    PubMed     Abstract available
    
    
    
15. LU Y, Xiong M, Sun RJ, Zhang JP, et al
    Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-10. doi: 10.1080/10428194.2022.2118527.
    PubMed     Abstract available
    
    
    
16. LU Y, Sun RJ, Zhang JP, Xu F, et al
    Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
    PubMed     Abstract available
    
    
    August 2022
17. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    PubMed     Abstract available
    
    
    July 2022
18. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.
    PubMed    
    
    
    
19. ZAMA D, Mondardini MC, Petris MG, Amigoni A, et al
    Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2095628.
    PubMed     Abstract available
    
    
    June 2022
20. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
    PubMed    
    
    
    
21. LIU Y, Qi L, Wang T, Zhou B, et al
    The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086245.
    PubMed    
    
    
    
22. HO M, Moscvin M, Low SK, Evans B, et al
    Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2084729.
    PubMed     Abstract available
    
    
    
23. LAHOUD OB, Landau H, Nguyen J, Devlin S, et al
    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Leuk Lymphoma. 2022 Jun 1:1-10. doi: 10.1080/10428194.2022.2062347.
    PubMed     Abstract available
    
    
    May 2022
24. HOWELLS L, Chan WY, Sanchez E, Horder J, et al
    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.
    Leuk Lymphoma. 2022 May 14:1-5. doi: 10.1080/10428194.2022.2074989.
    PubMed    
    
    
    
25. GERTZ MA, Warsame R, Muchtar E, Buadi F, et al
    Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 May 12:1-6. doi: 10.1080/10428194.2022.2074993.
    PubMed     Abstract available
    
    
    April 2022
26. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    PubMed     Abstract available
    
    
    
27. TAMAKI M, Nakasone H, Nakamura Y, Kawamura M, et al
    Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 7:1-9. doi: 10.1080/10428194.2022.2057486.
    PubMed     Abstract available
    
    
    March 2022
28. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available
    
    
    February 2022
29. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available
    
    
    
30. KAMADA Y, Arima N, Hayashida M, Nakamura D, et al
    Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
    Leuk Lymphoma. 2022 Feb 27:1-7. doi: 10.1080/10428194.2022.2043300.
    PubMed     Abstract available
    
    
    
31. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available
    
    
    January 2022
32. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available
    
    
    
33. IKEDA D, Tsushima T, Fukumoto A, Kuzume A, et al
    Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation.
    Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400.
    PubMed    
    
    
    December 2021
34. LU Y, Zhao YL, Xiong M, Sun RJ, et al
    Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
    Leuk Lymphoma. 2021 Dec 16:1-9. doi: 10.1080/10428194.2021.2015588.
    PubMed     Abstract available
    
    
    
35. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available
    
    
    November 2021
36. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    PubMed    
    
    
    
37. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.
    PubMed    
    
    
    
38. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    PubMed    
    
    
    
39. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available
    
    
    October 2021
40. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.
    PubMed    
    
    
    
41. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available
    
    
    
42. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    PubMed    
    
    
    September 2021
43. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    PubMed     Abstract available
    
    
    
44. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2295-2297.
    PubMed    
    
    
    
45. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2292-2294.
    PubMed    
    
    
    August 2021
46. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: